N-terminal pro-B-type natriuretic peptide is associated with clinical outcomes after transcatheter aortic valve replacement.

ABSTRACT:

Background

Limited data on the prognostic value of periprocedural changes of plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) after transcatheter aortic valve replacement (TAVR).

Methods

Data of plasma NT-proBNP were retrospectively collected in 357 patients before TAVR procedure and at discharge from January 1, 2018 to December 31, 2021 in our single center. Patients were grouped as responders and non-responders according to the NT-proBNP ratio (postprocedural NT-proBNP at discharge/ preprocedural NT-proBNP). Responders were defined as NT-proBNP ratio < 1 and non-responders were defined as NT-proBNP ratio ≥ 1. Outcomes were defined according to the Valve Academy Research Consortium (VARC)-3 criteria.

Results

A total of 234 patients (65.5%) and 123 patient

SUBMITTER: Yu J 

PROVIDER: S-EPMC10566171 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature